NRSN

NeuroSense Therapeutics Ltd.
CAPPED RATING

NeuroSense Therapeutics Ltd. (NRSN) is rated D- (1.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.0 / 5.0
D-
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.4 / 5.0
Profitability
F
Factor Score 0.7 / 5.0
Momentum
F
Factor Score 0.4 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.4
EV / EBITDA -0.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -80.6%
Price Return 12M -90.9%
Catalyst Signal 0.00
Market Cap $3.3M
TTM Revenue N/A
Price / Sales N/A
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) D (1.4) F (0.7) F (0.4) F (0.0) D- (1.0)
2026-11-06 C+ (2.5) D (1.4) F (0.7) F (0.4) F (0.0) D- (1.0)
2026-10-30 C+ (2.5) D (1.4) D- (0.7) F (0.5) C+ (2.7) D+ (1.6)
2026-10-23 C+ (2.5) D (1.4) F (0.7) F (0.6) C+ (2.6) D+ (1.6)
2026-10-16 C+ (2.5) D (1.4) F (0.7) F (0.6) C+ (2.6) D+ (1.6)
Page 1 of 4